Resul KAHRAMAN, ELİF SİNEM İPLİK, BEDİA ÇAKMAKOĞLU

Evaluation of TNF alpha G308A promoter gene polymorphism and serum TNF alpha levels in patients with inflammatory bowel disease in Turkish population

Tumor necrosis factor alpha (TNF-α) plays an important role in the pathophysiology of inflammatory bowel diseases (IBD). In this study, we aimed to investigate the role of TNF-α G308A promoter gene polymorphisms and TNF-α level in patients with IBD and their associations with clinical features of the patients. This study included 91 patients with inflammatory bowel disease (46 patients with ulcerative colitis (UC) and 45 patients with Crohn’s disease (CD)) and 129 healthy controls (HC). Polymerase chain reaction and restriction fragment length polymorphism techniques were both used to explain the frequency of TNF-α polymorphisms and the relationship about clinical outcomes of patients with IBD. There was no statistically significant difference about genotype frequencies and serum TNF-α level between the three groups (UC, CD, HC) (all p>0.05). TNF-α G308A genes polymorphisms were compared in terms of disease localization, behaviour, activity, the use of anti TNF-α treatment and operative status in patients with CD and UC. Similarly, there was no statistically significant difference about genotype frequencies in terms of all these parameters in patients with CD (p> 0.05). However, In patient with UC, the frequency of A allele and AG genotype was significantly increased in moderate and severe UC cases (p= 0.004). These findings suggest that TNF-α G308A gene polymorphism may be helpful in predicting the behavior of the disease in patients with ulcerative colitis but further studies are needed

PDF

___

Frolkis A, Dieleman LA, Barkema HW, et al. Alberta IBD Consortium. Environment and the inflammatory bowel diseases. Can J Gastroenterol. 2013;27:18-24.

Brant SR, Shugart YY. Inflammatory bowel disease gene hunting by linkage analysis: rationale, methodology, and present status of the field. Inflamm Bowel Dis. 2004;10:300-11.

Brant SR. Update on the heritability of inflammatory bowel disease: the importance of twin studies. Inflamm Bowel Dis. 2011;17:1-5.

Rodriguez-Bores L, Fonseca GC, Villeda MA, et al. Novel genetic markers in inflammatory bowel disease. World J Gastroenterol. 2007;13:5560-70.

Dechairo B, Dimon C, Van Heel D, et al. Replication and extension studies of inflammatory bowel disease susceptibility regions confirm linkage to chromosome 6p (IBD3). Eur J Hum Genet. 2001;9:627-33.

Muro M, López-Hernández R, Mrowiec A. Immunogenetic biomarkers in inflammatory bowel diseases: role of the IBD3 region. World J Gastroenterol. 2014;20:15037-48.

Komatsu M, Kobayashi D, Saito K, et al. Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem. 2001;47:1297-30

D’haens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: A European multicenter trial. Gastroenterology. 1999;116:1029-34.

Valesini G, Iannuccelli C, Marocchi E, et al. Biological and clinical effects of anti-TNFalpha treatment. Autoimmun Rev. 2007;7:35-41

Kontoyiannis D, Pasparakis M, Pizarro TT, et al. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements:implications for joint and gut-associated immunopathologies. Immunity. 1999;10:387-98.

11. Neurath MF, Fuss I, Pasparakis M, et al. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol. 1997;27:1743-50.

12. Wilson AG, de Vries N, Pociot F, et al. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med. 1993;177:557-60.

13. Wilson AG, Symons JA, McDowell TL, et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A. 1997;94:3195-3099.

14. González S, Rodrigo L, Martínez-Borra J, et al. TNF-alpha -308A promoter polymorphism is associated with enhanced TNF-alpha production and inflammatory activity in Crohn’s patients with fistulizing disease. Am J Gastroenterol. 2003;98:1101-6.

15. Van Assche G, Dignass A, Panes J, et al. The second European evidencebased consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. J of Crohn’s and Colitis. 2010;4:7-27.

16. Dichi I, Burini RC. Inflammatory bowel disease activity index: clinical and laboratory indicators. Arq Gastroenterol. 1995;32:121-30. 17.

17. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-53.

18. Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214:149-60.

19. Ferguson LR, Huebner C, Petermann I, et al. Single nucleotide polymorphism in the tumor necrosis factor-alpha gene affects inflammatory bowel diseases risk. World J Gastroenterol. 2008;14:4652-61.

20. Heresbach D, Ababou A, Bourienne A, et al. Polymorphism of the microsatellites and tumor necrosis factor genes in chronic inflammatory bowel diseases. Gastroenterol Clin Biol. 1997;21:555-61.

21. Castro-Santos P, Suarez A, Lopez-Rivas L, et al. TNF alpha and IL-10 gene polymorphisms in inflammatory bowel disease. Association of -1082 AA low producer IL-10 genotype with steroid dependency. Am J Gastroenterol. 2006;101:1039-47.

22. Sýkora J, Subrt I, Dìdek P, et al. Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G–>A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn’s disease. J Pediatr Gastroenterol Nutr. 2006;42:479-487.

23. Cucchiara S, Latiano A, Palmieri O, et al. Polymorphisms of tumor necrosis factor alpha but not MDR1 influence response to medical therapy in pediatriconset inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:1719.

24. Louis E, Peeters M, Franchimont D, et al. Tumor necrosis factor (TNF) gene polymorphism in Crohn’s disease (CD): influence on disease behavior? Clin Exp Immunol. 2000;119:64-8.

25. Bonyadi M, Abdolmohammadi R, Jahanafrooz Z, et al. TNF-alpha gene polymorphisms in Iranian Azari Turkish patients with inflammatory bowel diseases. Saudi J Gastroenterol. 2014;20:108-12.

26. Celik Y, Dagli U, Kiliç MY, et al. Cytokine gene polymorphisms in Turkish patients with inflammatory bowel disease. Scand J Gastroenterol. 2006;41:559-65.

27. Song Y, Wu KC, Zhang L, et al. Correlation between a gene polymorphism of tumor necrosis factor and inflammatory bowel disease. Chin J Dig Dis. 2005;6:170-4.

28. Cao Q, Zhu Q, Wu ML, et al. Genetic susceptibility to ulcerative colitis in the Chinese Han ethnic population: association with TNF polymorphisms. Chin Med J (Engl) 2006;119:1198-203.

29. Sashio H, Tamura K, Ito R, et al. Polymorphisms of the TNF gene and the TNF receptor super family member 1B gene are associated with susceptibility to ulcerative colitis and Crohn’s disease, respectively. Immunogenetics. 2002;53:1020-7.

30. Al-Meghaiseeb ES, Al-Robayan AA, Al-Otaibi MM, et al. Association of tumor necrosis factor-α and -β gene polymorphisms in inflammatory bowel disease. J Inflamm Res. 2016;9:133-40.